Abeona Therapeutics Inc. (ABEO): Price and Financial Metrics
ABEO Price/Volume Stats
| Current price | $7.53 | 52-week high | $9.01 |
| Prev. close | $7.93 | 52-week low | $2.83 |
| Day low | $7.51 | Volume | 245,958 |
| Day high | $8.17 | Avg. volume | 324,338 |
| 50-day MA | $7.36 | Dividend yield | N/A |
| 200-day MA | $5.02 | Market Cap | 205.98M |
ABEO Stock Price Chart Interactive Chart >
Abeona Therapeutics Inc. (ABEO) Company Bio
Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company iwas founded n 1989 and is based in Dallas, Texas.
Latest ABEO News From Around the Web
Below are the latest news stories about ABEONA THERAPEUTICS INC that investors may wish to consider to help them evaluate ABEO as an investment opportunity.
Those who invested in Abeona Therapeutics (NASDAQ:ABEO) a year ago are up 98%These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do... |
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On December 14, 2023, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to four individuals hired by Abeona, which equity awards relate to, in the |
ABEO: BLA for Pz-Cel (EB-101) Accepted with Priority Review; PDUFA Date of May 25, 2024…By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update BLA Accepted with Priority Review; PDUFA Action Date of May 25, 2024 On November 27, 2023, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) has accepted with Priority Review the Biologics License Application (BLA) to seek approval for prademagene zamikeracel |
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel), Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of pat |
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call TranscriptAbeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call Transcript November 16, 2023 Operator: Greetings, and welcome to the Abeona Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions]. Please note this conference is being recorded. I will now turn the conference over to your host, Mr. Greg Gin. Sir, you may begin. Greg Gin: Thank you, […] |
ABEO Price Returns
| 1-mo | -0.53% |
| 3-mo | 50.60% |
| 6-mo | 81.88% |
| 1-year | 139.05% |
| 3-year | -78.64% |
| 5-year | -96.22% |
| YTD | 50.30% |
| 2023 | 62.66% |
| 2022 | -63.44% |
| 2021 | -78.54% |
| 2020 | -51.99% |
| 2019 | -54.20% |
Continue Researching ABEO
Want to see what other sources are saying about Abeona Therapeutics Inc's financials and stock price? Try the links below:Abeona Therapeutics Inc (ABEO) Stock Price | Nasdaq
Abeona Therapeutics Inc (ABEO) Stock Quote, History and News - Yahoo Finance
Abeona Therapeutics Inc (ABEO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...